²é¿´: 1022  |  »Ø¸´: 5
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

ÂäåÈ

Òø³æ (СÓÐÃûÆø)

[ÇóÖú] ¼ÌÐøÇóÖú£¡£¡£¡¼±£¡£¡£¡ ·­ÒëÒ»¶Î»°

The topic of sex differences in adverse responses to drugs is
gaining much attention at the moment, as data in regards to gender
dimorphic toxicity in the clinic are rapidly emerging [4,5]. Much of
these data rule out some obvious gender differences (such as body
weight and body fat) [6,7] as major causal factors. However, it is
possible that hormonal signaling underlies these basic differences
which are poorly understood at the moment. Hence, there is a
compelling need for basic research at the molecular level, in order
to comprehend and thus perhaps prevent these sex differences in
adverse responses in the future.
    Canis familiaris, the domestic dog, is a major preclinical animal
species for drug development. The species is used in a wide range of
studies involving safety and efficacy, including regulatory toxicology
studies and cardiovascular telemetry studies [1] and thereby in
translational safety and dose-prediction models to human [2].
Therefore, in the current study, we investigate gene expression in
the major drug metabolizing tissues (in addition to heart tissues)
to see whether any sex differences occur - and if so - to investigate
the potential implications for drug development. Another issue to
consider is that apart from regulatory toxicology studies, preclinical
animal studies tend to be predominantly male [3] and the concern is
that sex differences, which may translate to humans in the clinic, are
being overlooked.
    In this study we investigated gene expression profiles in dog
heart tissues (ventricle and atrium), along with the major drug
metabolizing tissues of the kidney (medulla and cortex), liver and
small bowel (gut ileum) and used pathway analysis tools to evaluate
whether major sex differences were occurring.

» ²ÂÄãϲ»¶

http://bbs.kuakao.com/?fromuid=8888
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

8814402

ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï
sltmac(½ð±Ò+2): ллӦÖú~~ 2011-05-31 15:23:37
ÂäåÈ(½ð±Ò+10, ·­ÒëEPI+1): лл¹Ø×¢ 2011-05-31 19:52:20
The topic of sex differences in adverse responses to drugs is gaining much attention at the moment, as data in regards to gender dimorphic toxicity in the clinic are rapidly emerging [4,5]. µ±ÓйØÐÔ±ð¶þ̬ÐÔ¶¾ÐÔÏÖÏóÔÚÁÙ´²¿ìËÙ³öÏÖʱ£¬¶ÔÔÚÒ©Îï²»Á¼·´Ó¦ÖеÄÐÔ±ð²îÒì»°Ìâ½¥½¥ÒýÆðÁ˸ü¶àµÄ×¢Òâ¡£Much of these data rule out some obvious gender differences (such as body weight and body fat) [6,7] as major causal factors. ÕâЩ×ÊÁÏÖеĴó¶àÊý¶¼½«Ä³Ð©Ã÷ÏÔµÄÐÔ±ð²îÒ죨ÖîÈçÌåÖØºÍÖ¬·¾º¬Á¿£©×÷ΪÖ÷ÒªÆðÒò¡£However, it is possible that hormonal signaling underlies these basic differences which are poorly understood at the moment. È»¶ø£¬¼¤ËØÐźÅÊÇÕâЩ»ù´¡²îÒìµÄ»ù´¡£¬¿ÉÄÜÕâЩÊÂʵÔÚÄÇʱ»¹ÈÏʶ²»×ã¡£ Hence, there is a compelling need for basic research at the molecular level, in order to comprehend and thus perhaps prevent these sex differences in adverse responses in the future.Òò´Ë£¬¼±ÐèÔÚ·Ö×Óˮƽ½øÐлù´¡Ñо¿£¬ÒÔÀí½âºÍÔÚ½«À´·ÀÖ¹Ò©Îï²»Á¼·´Ó¦ÖеÄÐÔ±ð²îÒì¡£
2Â¥2011-05-31 11:44:26
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

8814402

ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

ÆäÓàµÄÏÂÎçÔÙÒ룬»Ø¼Ò³ÔÎç·¹ÁË
3Â¥2011-05-31 11:45:25
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

8814402

ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

ÂäåÈ(½ð±Ò+5): »¹ÊDz»Ì«Í¨ 2011-05-31 19:52:58
Canis familiaris, the domestic dog, is a major preclinical animal species for drug development. ¼ÒÈ®ÊÇÁÙ´²Ç°Ò©ÎïÑз¢Öг£ÓõÄÖ÷ҪʵÑ鶯Îï¡£ The species is used in a wide range of studies involving safety and efficacy, including regulatory toxicology studies and cardiovascular telemetry studies [1] and thereby in translational safety and dose-prediction models to human [2]. ÕâһʵÑ鶯ÎïÖÖÀàÔÚ°²È«ÐÔºÍÓÐЧÐÔÑо¿Öж¼Óй㷺µÄÓ¦Ó㬰üÀ¨µ÷¿Ø¶¾ÀíѧºÍÐÄѪ¹ÜÒ£²â¼¼ÊõÑо¿ÖеÄÓ¦Óã¬Òò¶ø¿ÉÓÃ×÷ת¼°²È«ÐÔºÍÈ˼ÁÁ¿Ô¤²âµÄÄ£ÐÍ¡£
4Â¥2011-05-31 11:51:45
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

8814402

ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

ÂäåÈ(½ð±Ò+15): 5 2011-05-31 19:54:01
Therefore, in the current study, we investigate gene expression in the major drug metabolizing tissues (in addition to heart tissues) to see whether any sex differences occur - and if so - to investigate the potential implications for drug development.Òò´Ë£¬ ÔÚµ±Ç°Ñо¿ÖУ¬ÎÒÃÇÑо¿Ö÷ÒªÒ©Îï´úлÆ÷¹Ù×éÖ¯£¨°üÀ¨ÐÄÔࣩÖеĻùÒò±í´ï£¬ÒÔÈ·¶¨ÐÔ±ð²îÒìÊÇ·ñ´æÔÚ£¬Èç¹û´æÔÚ£¬½øÒ»²½Ñо¿ÆäÔÚÒ©ÎïÑз¢ÖеÄDZÔÚÒâÒå¡£Another issue to consider is that apart from regulatory toxicology studies, preclinical animal studies tend to be predominantly male [3] and the concern is that sex differences, which may translate to humans in the clinic, are being overlooked.ÁíÒ»¸öÒª¿¼ÂǵÄÊÇ£¬ÁÙ´²Ç°¶¯ÎïÑо¿Óëµ÷¿Ø¶¾Àíѧ²»Í¬£¬ÇãÏòÓÚÖ÷µ¼ÐÔµØÊ¹ÓÃÐÛÐÔ¶¯ÎÕâÑùÑо¿¾Í»á´æÔÚÐÔ±ð²îÒìÎÊÌ⣬²¢ÔÚÁÙ´²Öдøµ½ÈËÉÏ£¬ÕâÒ»ÎÊÌâÕýÔÚ±»ºöÂÔ¡£
    In this study we investigated gene expression profiles in dog heart tissues (ventricle and atrium), along with the major drug metabolizing tissues of the kidney (medulla and cortex), liver and small bowel (gut ileum) and used pathway analysis tools to evaluate whether major sex differences were occurring. ±¾Ñо¿ÖÐÎÒÃÇÑо¿Á˼ÒÈ®ÐÄÔࣨÐÄÊÒºÍÐÄ·¿£©ÒÔ¼°Ö÷ÒªÒ©Îï´úлÓÐ¹ØÆ÷¹Ù×éÖ¯ÈçÉö£¨ËèÖÊºÍÆ¤ÖÊ£©¸ÎºÍС³¦µÄ»ùÒò±í´ï£¬²¢Í¨¹ýͨ··ÖÎö¹¤¾ßÀ´ÆÀ¹ÀÊÇ·ñ´æÔÚÖØÒªµÄÐÔ±ð²îÒì¡£
5Â¥2011-05-31 14:40:00
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

8814402

ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

Canis familiaris, the domestic dog, is a major preclinical animal species for drug development. ¼ÒÈ®ÊÇÁÙ´²Ç°Ò©ÎïÑз¢Öг£ÓõÄÖ÷ҪʵÑ鶯Îï¡£ The species is used in a wide range of studies involving safety and efficacy, including regulatory toxicology studies and cardiovascular telemetry studies [1] and thereby in translational safety and dose-prediction models to human [2]. ÕâһʵÑ鶯ÎïÖÖÀàÔÚ°²È«ÐÔºÍÓÐЧÐÔÑо¿Öж¼Óй㷺µÄÓ¦Ó㬰üÀ¨µ÷¿Ø¶¾ÀíѧºÍÐÄѪ¹ÜÒ£²â¼¼ÊõÑо¿ÖеÄÓ¦Óã¬Òò¶ø¿ÉÓÃ×÷ת¼°²È«ÐÔºÍÈ˼ÁÁ¿Ô¤²âµÄÄ£ÐÍ¡£Therefore, in the current study, we investigate gene expression in the major drug metabolizing tissues (in addition to heart tissues) to see whether any sex differences occur - and if so - to investigate the potential implications for drug development.Òò´Ë£¬ ÔÚµ±Ç°Ñо¿ÖУ¬ÎÒÃÇÑо¿Ö÷ÒªÒ©Îï´úлÆ÷¹Ù×éÖ¯£¨°üÀ¨ÐÄÔࣩÖеĻùÒò±í´ï£¬ÒÔÈ·¶¨ÐÔ±ð²îÒìÊÇ·ñ´æÔÚ£¬Èç¹û´æÔÚ£¬½øÒ»²½Ñо¿ÆäÔÚÒ©ÎïÑз¢ÖеÄDZÔÚÒâÒå¡£Another issue to consider is that apart from regulatory toxicology studies, preclinical animal studies tend to be predominantly male [3] and the concern is that sex differences, which may translate to humans in the clinic, are being overlooked.ÁíÒ»¸öÒª¿¼ÂǵÄÊÇ£¬ÁÙ´²Ç°¶¯ÎïÑо¿Óëµ÷¿Ø¶¾Àíѧ²»Í¬£¬ÇãÏòÓÚÖ÷µ¼ÐÔµØÊ¹ÓÃÐÛÐÔ¶¯ÎÕâÑùÑо¿¾Í»á´æÔÚÐÔ±ð²îÒìÎÊÌ⣬²¢ÔÚÁÙ´²Öдøµ½ÈËÉÏ£¬ÕâÒ»ÎÊÌâÕýÔÚ±»ºöÂÔ¡£
    In this study we investigated gene expression profiles in dog heart tissues (ventricle and atrium), along with the major drug metabolizing tissues of the kidney (medulla and cortex), liver and small bowel (gut ileum) and used pathway analysis tools to evaluate whether major sex differences were occurring. ±¾Ñо¿ÖÐÎÒÃÇÑо¿Á˼ÒÈ®ÐÄÔࣨÐÄÊÒºÍÐÄ·¿£©ÒÔ¼°Ö÷ÒªÒ©Îï´úлÓÐ¹ØÆ÷¹Ù×éÖ¯ÈçÉö£¨ËèÖÊºÍÆ¤ÖÊ£©¸ÎºÍС³¦µÄ»ùÒò±í´ï£¬²¢Í¨¹ýͨ··ÖÎö¹¤¾ßÀ´ÆÀ¹ÀÊÇ·ñ´æÔÚÖØÒªµÄÐÔ±ð²îÒì¡£
6Â¥2011-05-31 15:40:18
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ÂäåÈ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ¿¼Ñе÷¼Á +4 À´ºÃÔËÀ´À´À´ 2026-03-21 4/200 2026-03-22 12:15 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 286Çóµ÷¼Á +10 Faune 2026-03-21 10/500 2026-03-21 23:34 by 314126402
[¿¼ÑÐ] »¯Ñ§µ÷¼Á +5 yzysaa 2026-03-21 5/250 2026-03-21 22:12 by peike
[¿¼ÑÐ] Ò»Ö¾Ô¸¶«»ª´óѧ¿ØÖÆÑ§Ë¶320Çóµ÷¼Á +3 Grand777 2026-03-21 3/150 2026-03-21 19:23 by ¼òÖ®-
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄÏ´ó£¬0703»¯Ñ§£¬·ÖÊý336£¬Çóµ÷¼Á +3 ÊÕµ½VS 2026-03-21 3/150 2026-03-21 18:42 by ѧԱ8dgXkO
[¿¼ÑÐ] Ò»Ö¾Ô¸Éî´ó£¬0703»¯Ñ§£¬×Ü·Ö302£¬Çóµ÷¼Á +4 ÆßÔÂ-ÆßÆß 2026-03-21 4/200 2026-03-21 18:20 by ѧԱ8dgXkO
[¿¼ÑÐ] 297Çóµ÷¼Á +11 Ï·¾«µ¤µ¤µ¤ 2026-03-17 12/600 2026-03-21 17:47 by ColorlessPI
[¿¼ÑÐ] 336Çóµ÷¼Á +5 rmc8866 2026-03-21 5/250 2026-03-21 17:24 by ѧԱ8dgXkO
[¿¼ÑÐ] 271²ÄÁϹ¤³ÌÇóµ÷¼Á +8 .6lL 2026-03-18 8/400 2026-03-21 00:58 by JourneyLucky
[¿¼ÑÐ] ²ÄÁÏר˶ӢһÊý¶þ306 +7 z1z2z3879 2026-03-18 7/350 2026-03-20 23:48 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸Öк£Ñó²ÄÁϹ¤³Ìר˶330·ÖÇóµ÷¼Á +8 С²Ä»¯±¾¿Æ 2026-03-18 8/400 2026-03-20 23:16 by JourneyLucky
[¿¼ÑÐ] 304Çóµ÷¼Á +7 ˾¿Õ. 2026-03-18 7/350 2026-03-20 23:08 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸Î÷°²½»Í¨´óѧ ѧ˶ 354Çóµ÷¼Á211»òÕß˫һÁ÷ +3 ÎÒÏëÒª¶ÁÑо¿Éú 2026-03-20 3/150 2026-03-20 20:13 by JourneyLucky
[¿¼ÑÐ] 086500 325 Çóµ÷¼Á +3 Áì´øÐ¡ÐÜ 2026-03-19 3/150 2026-03-20 18:38 by ¾¡Ë´Ò¢1
[¿¼ÑÐ] Çóµ÷¼Á +3 °µÓ¿afhb 2026-03-16 3/150 2026-03-20 00:28 by ºÓÄÏ´óѧУÓÑ
[¿¼ÑÐ] 0854¿É¿çµ÷¼Á£¬Ò»×÷Ò»ÏîºËÐÄÂÛÎÄÎåÏîרÀû£¬Ê¡¡¢¹ú¼¶Ö¤Êé40+ÊýÒ»Ó¢Ò»287 +8 СÀî0854 2026-03-16 8/400 2026-03-18 14:35 by ²«»÷518
[¿¼ÑÐ] ²ÄÁÏ£¬·ÄÖ¯£¬ÉúÎ0856¡¢0710£©£¬»¯Ñ§ÕÐÉúÀ² +3 Eember. 2026-03-17 9/450 2026-03-18 10:28 by Eember.
[¿¼ÑÐ] 334Çóµ÷¼Á +3 Ö¾´æ¸ßÔ¶ÒâÔÚ»úÐ 2026-03-16 3/150 2026-03-18 08:34 by lm4875102
[¿¼²©] 26²©Ê¿ÉêÇë +3 1042136743 2026-03-17 3/150 2026-03-17 23:30 by ÇáËɲ»ÉÙËæ
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄϾ©´óѧ£¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ì£¬µ÷¼Á +4 Jy? 2026-03-16 4/200 2026-03-17 11:02 by gaoqiong
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û